en English
en Englishfr Frenchde Germanit Italianru Russianes Spanish

Danone to sell US organic dairy units to PE firm Platinum Equity

Danone to sell US organic dairy units to PE firm Platinum Equity By Reuters

Breaking News

‘;

Stock Markets

Published Jan 02, 2024 12:00AM ET
Updated Jan 02, 2024 03:47PM ET

© Reuters. FILE PHOTO: Dairy products of French food group Danone are seen in a supermarket in Nice, France, January 9, 2023. REUTERS/Eric Gaillard/File Photo

(Reuters) – French food group Danone said on Tuesday it had signed an agreement to sell its premium organic dairy units in the United States to investment firm Platinum Equity.

The sale of the Horizon Organic and Wallaby businesses is part of the company’s portfolio review and asset rotation program the company announced in March 2022, Danone said in a statement, without disclosing the financial details of the deal.

“This sale, once completed, will allow us to concentrate further on our current portfolio of strong, health-focused brands and reinvest in our growth priorities,” said Danone CEO Antoine de Saint-Affrique.

Danone will retain a minority stake in the business, the company added.

Danone declined to comment on the deal value, but added that the sale would have an impact on its 2024 financials.

Platinum Equity did not immediately respond to a Reuters request for comment on the deal value of this transaction.

The Paris-based company said in January last year that it was exploring strategic options, including a potential sale, for its organic dairy activity in the U.S.

Danone’s organic dairy activity in the U.S. comprised of the Horizon Organic and Wallaby businesses with a portfolio of organic dairy products, including milk, creamers, yogurt, cheese and butter.

It represented approximately 3% of Danone’s global revenues and had a dilutive impact on Danone’s like-for-like sales growth and recurring operating margin in 2022.

Danone to sell US organic dairy units to PE firm Platinum Equity

Our Apps



Terms And Conditions
Privacy Policy
Risk Warning
Do not sell my personal information

© 2007-2024 Fusion Media Limited. All Rights Reserved.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

 

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous post US FDA approvals bounce back in 2023, sparking hopes of a biotech recovery
Next post FTC reaches settlement with XCast Labs over illegal robocalls